Keri Carbaugh | Feb 17, 2017

Shire provides latest data on Hunter's syndrome, Gaucher disease

The global biotechnology company Shire Plc offered its latest insights into certain lysosomal diseases (LSDs) through presentations, satellite symposia and booths at the recent 13th annual WORLD Symposium in San Diego, the company said.

The symposium, which wrapped up on Friday after a week of “shining light on science, research and clinical trials for lysosomal diseases,” is aimed at providing an overview of management and diagnostic options for patients with lysosomal diseases, as well as pointing out areas that need more clinical or even basic research.

“We are proud of our ongoing commitment to patients with rare genetic diseases and look forward to showcasing the depth and breadth of our scientific research across the LSDs,” Dr. Hartmann Wellhoefer, vice president and head of Medical Affairs and Genetic Diseases at Shire, said. “The data … represent our continued focus on advancing the diagnosis, treatment and management of life-altering diseases.”

Shire offered its results of a three-year study on Hunter syndrome’s effects on cognition, an analysis that looked at defining characteristics of patients with Gaucher disease type III, and the effects Gaucher disease can have on pregnancy.

Organizations in this story

+ Shire